Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Hereditary Angioedema Clinical Trials

A listing of Hereditary Angioedema medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (14) clinical trials

The purpose of this clinical research study to test how well and how safe an investigational medication works in children and adolescent with HAE. Winthrop University Hospital Clinical Trials Center is conducting this clinical research study for children and adolescents, ages 2- 15 years old who have been diagnosed with ...

Phase N/A

Winthrop University Hospital Clinical Trials Center is Seeking participants that are at least 16 years of age and have been diagnosed with Acute Hereditary Angioedema. Hereditary Angioedema (HAE) is a very rare and potentially life-threatening genetic condition that occurs in about 1 in 10,000 to 1 in 50,000 people. HAE ...

Phase

Winthrop University Hospital Clinical Trials Center is seeking volunteers with inadequately controlled Hereditary Angioedema (HAE) for a clinical research study to test a medication already approved by the Food and Drug Administration (FDA) to investigate the safety and effectiveness of a higher dosage not approved by the FDA. Patient Inclusion ...

Phase N/A

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema

This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with BCX7353 (2 attacks) or placebo (1 attack), in a randomly ...

Phase

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

This is an open-label study to evaluate the long term safety and effectiveness of oral treatment with BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE.

Phase

Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)

The Firazyr Patient Registry is a multicenter, prospective, observational study for patients treated with Firazyr in countries where it is currently approved. The entry of patients into the Firazyr Registry is at the discretion of the physician and the patient and is not a pre-requisite for prescribing Firazyr.

Phase N/A

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including 13 years of age.

Phase

Biomarker for Hereditary Angioedema Disease Type 1

Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Usually, this swelling is ...

Phase N/A

Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population

In emergency room, this is crucial to diagnose an acute attack of hereditary angioedema (HAE) to quickly provide the efficient treatment. Currently, there is no specific biomarker for acute attack of bradykinin-mediated angioedema to help clinicians for patient care. However, previous works are carried out for that purpose. All the ...

Phase N/A